Picture loading failed.

Anti-TNFRSF8 therapeutic antibody (Pre-made Brentuximab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-080-1mg 1mg 3090
GMP-Bios-ab-080-10mg 10mg 21890
GMP-Bios-ab-080-100mg 100mg 148000
GMP-Bios-ab-080-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFRSF8 therapeutic antibody (Pre-made Brentuximab biosimilar,Whole mAb ADC)
INN Name Brentuximab
TargetTNFRSF8
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesBristol-Myers Squibb;Celgene Corporation;Dana-Farber Cancer Institute;Fondazione Italiana Linfomi;Fox Chase Cancer Center;Immune Tolerance Network;Lymphoma Academic Research Organisation;Massachusetts General Hospital;National Cancer Institute (USA);National Institute of Allergy and Infectious Diseases;Seattle Genetics;Stanford University;Takeda;Takeda Oncology;UNC Lineberger Comprehensive Cancer Center;Washington University School of Medicine
Conditions ApprovedAnaplastic large cell lymphoma;Cutaneous T-cell lymphoma;Hodgkin's disease;Mycosis fungoides;T-cell lymphoma
Conditions ActiveAdult T-cell leukaemia-lymphoma;Diffuse large B cell lymphoma;Germ cell and embryonal neoplasms;Mastocytosis;Mesothelioma;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma;Sezary syndrome;Diffuse scleroderma
Conditions DiscontinuedGraft-versus-host disease;Leukaemia;Multiple myeloma;Solid tumours;Systemic lupus erythematosus
Development Techna